Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody.
暂无分享,去创建一个
T. Waldmann | J. Carrasquillo | E. Dadachova | K. Garmestani | W. Eckelman | K. Wong | C. Paik | A. Yordanov | Z. Yao | L. Park
[1] S. Mirzadeh,et al. In vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates. , 2001, Cancer biotherapy & radiopharmaceuticals.
[2] M. J. Mattes,et al. Limitations in the use of low pH extraction to distinguish internalized from cell surface-bound radiolabeled antibody. , 2000, Nuclear medicine and biology.
[3] L. Chappell,et al. Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb. , 2000, Nuclear medicine and biology.
[4] Y. Erdi,et al. Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[5] D. Bigner,et al. Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate. , 1999, Nuclear medicine and biology.
[6] T. Waldmann,et al. Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[7] D. Scheinberg,et al. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[8] G. Griffiths,et al. Intracellular processing of 99Tcm-antibody conjugates. , 1998, Nuclear medicine communications.
[9] J. Humm,et al. Radioimmunotherapy with alpha-emitting nuclides , 1998, European Journal of Nuclear Medicine.
[10] M. Brechbiel,et al. In vivo evaluation of a lead-labeled monoclonal antibody using the DOTA ligand , 1998, European Journal of Nuclear Medicine.
[11] G. Henriksen,et al. ISOLATION OF CYCLOTRON PRODUCED 205BI, 206BI AND 203PB USING A LEAD-SELECTIVE EXTRACTION CHROMATOGRAPHIC RESIN , 1998 .
[12] T. Waldmann,et al. Preparation of 211At-labeled humanized anti-Tac using 211At produced in disposable internal and external bismuth targets. , 1998, Nuclear medicine and biology.
[13] T. Waldmann,et al. Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[14] D. Goldenberg,et al. The advantage of residualizing radiolabels for targeting B‐cell lymphomas with a radiolabeled anti‐CD22 monoclonal antibody , 1997, International journal of cancer.
[15] L. Holder. Principles of Nuclear Medicine. 2nd ed , 1996 .
[16] I. Bernstein,et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. , 1996, Cancer research.
[17] D. Bigner,et al. Radioimmunotherapy with α-Particle Emitting Radioimmunoconjugates , 1996 .
[18] D. Bigner,et al. Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates. , 1996, Acta oncologica.
[19] M J Welch,et al. Identification of metabolites of 111In-diethylenetriaminepentaacetic acid-monoclonal antibodies and antibody fragments in vivo. , 1995, Cancer research.
[20] D. Goldenberg,et al. Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotope in tumors. , 1995, Cancer research.
[21] Zsolt Szabo,et al. Principles of Nuclear Medicine , 1995 .
[22] G. Griffiths,et al. The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[23] I. Pastan,et al. Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[24] M. Welch,et al. Intracellular metabolism of indium-111-DTPA-labeled receptor targeted proteins. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[25] I. Pastan,et al. Preclinical evaluation of 111In-labeled B3 monoclonal antibody: biodistribution and imaging studies in nude mice bearing human epidermoid carcinoma xenografts. , 1993, Cancer research.
[26] S. Larson,et al. Recent achievements in the development of radiolabeled monoclonal antibodies for diagnosis, therapy and biologic characterization of human tumors. , 1993, Acta oncologica.
[27] D. Goldenberg,et al. The fate of antibodies bound to the surface of tumor cells in vitro. , 1992, Cancer research.
[28] S. Anderson,et al. Intracellular catabolism of radiolabeled anti-CD3 antibodies by leukemic T cells. , 1991, Cellular immunology.
[29] S. Larson,et al. Differential cellular catabolism of 111In, 90Y and 125I radiolabeled T101 anti-CD5 monoclonal antibody. , 1990, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.
[30] C. Coleman,et al. Alpha particle radio-immunotherapy: animal models and clinical prospects. , 1989, International journal of radiation oncology, biology, physics.
[31] A. Chang,et al. Differences in biodistribution of indium-111-and iodine-131-labeled B72.3 monoclonal antibodies in patients with colorectal cancer. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[32] J. Mulshine,et al. Indium-111 T101 monoclonal antibody is superior to iodine-131 T101 in imaging of cutaneous T-cell lymphoma. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[33] M. Lagunas-Solar,et al. Cyclotron production of no-carrier-added 206Bi (6.24 d) and 205Bi (15.31 d) as tracers for biological studies and for the development of alpha-emitting radiotherapeutic agents. , 1987, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.
[34] R. Dillman,et al. Continuous infusion of T101 monoclonal antibody in chronic lymphocytic leukemia and cutaneous T-cell lymphoma. , 1986, Journal of biological response modifiers.
[35] W. Pardridge,et al. Rapid Sequestration and Degradation of Somatostatin Analogues by Isolated Brain Microvessels , 1985, Journal of neurochemistry.
[36] R. Dillman,et al. Induction of in vitro and in vivo antigenic modulation by the anti-human T-cell monoclonal antibody T101. , 1984, Cancer research.
[37] R. Schroff,et al. Enhancing effects of monocytes on modulation of a lymphocyte membrane antigen. , 1984, Journal of immunology.
[38] P. Bunn,et al. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. , 1984, Journal of immunological methods.
[39] I. Royston,et al. Alterations in cell surface phenotype of T- and B-cell chronic lymphocytic leukemia cells following in vitro differentiation by phorbol ester. , 1984, Journal of the National Cancer Institute.
[40] I. Royston,et al. Human T cell antigens defined by monoclonal antibodies: the 65,000-dalton antigen of T cells (T65) is also found on chronic lymphocytic leukemia cells bearing surface immunoglobulin. , 1980, Journal of immunology.
[41] F. Greenwood,et al. THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY. , 1963, The Biochemical journal.
[42] F. Greenwood,et al. Preparation of Iodine-131 Labelled Human Growth Hormone of High Specific Activity , 1962, Nature.